Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 70 entries
View as:

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

Phase: N/A Priority: Normal
NCT ID: NCT02162771 Org: User:
Start: 07/14/14 End: 12/29/18 Due: 12/29/19

To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT03707535 Org: User:
Start: 11/12/18 End: 03/05/21 Due: 03/05/22

A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06939595 Org: User:
Start: 01/30/25 End: 07/31/28 Due: 07/31/29

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06951828 Org: User:
Start: 05/31/25 End: 04/30/26 Due: 04/30/27

Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01534884 Org: User:
Start: 02/29/12 End: 02/28/14 Due: 02/28/15

An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA

Phase: N/A Priority: Normal
NCT ID: NCT02557295 Org: User:
Start: 12/17/13 End: 03/02/20 Due: 03/02/21

An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1

Phase: N/A Priority: Normal
NCT ID: NCT01571206 Org: User:
Start: 03/31/12 End: 05/31/13 Due: 05/31/14

Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial

Phase: N/A Priority: Normal
NCT ID: NCT01534949 Org: User:
Start: 02/29/12 End: 02/28/13 Due: 02/28/14

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

Phase: N/A Priority: Normal
NCT ID: NCT03945019 Org: User:
Start: 10/28/19 End: 08/22/23 Due: 08/22/24

A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05363384 Org: User:
Start: 06/11/22 End: 07/12/22 Due: 07/12/23

Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02096861 Org: User:
Start: 09/19/14 End: 02/15/17 Due: 02/15/18

A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA

Phase: N/A Priority: Normal
NCT ID: NCT03147248 Org: User:
Start: 09/12/16 End: 04/15/19 Due: 04/15/20

To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04018313 Org: User:
Start: 05/28/20 End: 04/30/21 Due: 04/30/22

To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT05495568 Org: User:
Start: 11/07/22 End: 02/05/24 Due: 02/05/25

A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04673786 Org: User:
Start: 01/11/21 End: 05/12/22 Due: 05/12/23

A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05188378 Org: User:
Start: 12/22/21 End: 01/31/23 Due: 01/31/24

A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT04171414 Org: User:
Start: 09/09/19 End: 04/24/20 Due: 04/24/21

Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT04739306 Org: User:
Start: 07/22/21 End: 04/24/23 Due: 04/24/24

Long-Term Efficacy and Safety of CT-P10 in Patients With RA

Phase: N/A Priority: Normal
NCT ID: NCT01873443 Org: User:
Start: 05/31/13 End: 10/31/14 Due: 10/31/15

A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05363592 Org: User:
Start: 06/25/22 End: 07/25/22 Due: 07/25/23

Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06037395 Org: User:
Start: 10/06/21 End: 10/20/22 Due: 10/20/23

A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model

Phase: N/A Priority: Normal
NCT ID: NCT02071914 Org: User:
Start: 02/15/14 End: 06/19/14 Due: 06/19/15

A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT03789292 Org: User:
Start: 11/26/18 End: 04/24/20 Due: 04/24/21

To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03970824 Org: User:
Start: 05/31/19 End: 01/15/20 Due: 01/15/21

To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17

Phase: N/A Priority: Normal
NCT ID: NCT04295356 Org: User:
Start: 06/21/19 End: 11/15/19 Due: 11/15/20